Hydra teams up with BI again

Cambridge, Mass.-based Hydra Biosciences inked its second partnership with Boehringer Ingelheim in as many years. The partners announced 13 April that they have entered into a research collaboration to identify transient receptor potential (TRP) inhibitors for the treatment of renal diseases. Hydra received an undisclosed upfront payment and is eligible to receive research funding, milestone payments and tiered royalties on any products that result. The tie-up comes exactly a year after the pair inked their first partnership in which they agreed to develop small molecule TRPC4/5 inhibitors for central nervous system diseases and disorders. Hydra received an upfront payment and research funding with the potential to earn additional milestone fees and royalties.